The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy for an undisclosed sum.
- The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.
- The U.S. government in November had signed contracts worth about $1 billion for an unknown number of doses of the treatment after saying it would control the distribution of sotrovimab.
- Related: Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19.
- GSK and Vir said they expect to produce roughly 2 million doses of sotrovimab globally in 1H of 2022.
- Price Action: VIR stock is down 0.42% at $33.28, while GSK shares are up 0.28% at $44.97 during the market session on the last check Tuesday.
